Islet Sciences Inc Stock

Equities

Delayed OTC Markets Other stock markets 09:53:58 2017-07-26 am EDT			5-day change	1st Jan Change
0.0127 ^USD	+5.75%		+5.75%	-76.93%

Duration

Period

Style

Islet Sciences, Inc. Publishes Data Supporting Remogliflozin Etabonate as a Potential Treatment for NAFLD and NASH	15-05-04	GL
Islet Sciences, Inc. Presented at 50th International Liver Conference	15-04-23	GL
Islet Sciences, Inc. COO to Present at Metabolic Leaders Forum	15-03-24	GL
Islet Sciences, Inc. COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)	15-03-09	GL
Islet Sciences, Inc. Confirms Issuance of U.S. Patent for Using SGLT2 Inhibitors to Treat NASH/NAFLD	15-03-05	GL

1 day

+5.75%

Sector

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	-0.10%	42.63B
LONZA GROUP AG	+50.98%	42.32B
MODERNA, INC.	+4.43%	40.26B
CELLTRION, INC.	-11.36%	27.27B
ICON PUBLIC LIMITED COMPANY	+5.67%	25.24B
ALNYLAM PHARMACEUTICALS, INC.	-22.84%	18.78B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.20%	12.39B
MEDPACE HOLDINGS, INC.	+26.30%	12.24B
UNITED THERAPEUTICS CORPORATION	+6.91%	10.95B